Total for the last 12 months
number of access : ?
number of downloads : ?
ID 116246
Author
Tanaka, Takahiro Tokushima University
Kagiwada, Harumi National Institute of Advanced Industrial Science and Technology
Kitazawa, Masashi SOCIUM
Fukui, Kazuhiko National Institute of Advanced Industrial Science and Technology|SOCIUM
Horimoto, Katsuhisa National Institute of Advanced Industrial Science and Technology|SOCIUM
Keywords
hepatocellular carcinoma
lenvatinib
sorafenib
hepatic reserve function
FGFR
Content Type
Journal Article
Description
The efficacy and safety of lenvatinib (LEN) as a second/third-line treatment for unresectable hepatocellular carcinoma (HCC) after sorafenib (SOR) therapy remains unknown. We evaluated the outcomes of second/third-line LEN treatment, investigated the sensitivity of a SOR-resistant HCC cell line (PLC/PRF5-R2) to LEN, and assessed their signal transduction pathways by protein array analysis. We retrospectively enrolled 57 patients with unresectable HCC. Fifty-three radiologically evaluated patients comprised 34 molecular-targeted agent (MTA)-naive (first-line), nine intolerant to SOR (second-line), and 10 resistant to regorafenib (third-line). The objective response rates (ORRs) were 61.8% in first-line, 33.3% in second-line, and 20.0% in third-line groups. The overall survival (OS) in the first-line was significantly longer than that in the third-line group (p < 0.05). Patients with better liver functional reserves (child score, ALBI grade) exhibited higher ORR and longer OS. The IC50 of LEN against PLC/PRF5-R2 was significantly higher than that against PLC/PRF5. LEN significantly inhibited more LEN-related signal transduction pathways in PLC/PRF5 than in PLC/PRF5-R2 cells. This suggests that LEN is active and safe as a second/third-line treatment for unresectable HCC. LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR.
Journal Title
Oncotarget
ISSN
19492553
Publisher
Impact Journals
Volume
11
Issue
26
Start Page
2531
End Page
2542
Published Date
2020-06-30
Rights
This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0)(https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
University Hospital
Medical Sciences